Last reviewed · How we verify
ondansetron and dyclonine hydrochloride
Ondansetron blocks serotonin 5-HT3 receptors to prevent nausea and vomiting, while dyclonine hydrochloride provides local anesthetic action.
Ondansetron blocks serotonin 5-HT3 receptors to prevent nausea and vomiting, while dyclonine hydrochloride provides local anesthetic action. Used for Chemotherapy-induced nausea and vomiting (CINV), Postoperative nausea and vomiting (PONV), Radiation-induced nausea and vomiting.
At a glance
| Generic name | ondansetron and dyclonine hydrochloride |
|---|---|
| Sponsor | Peking Union Medical College Hospital |
| Drug class | 5-HT3 receptor antagonist with local anesthetic |
| Target | 5-HT3 receptor; local anesthetic (sodium channel blockade) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology; Oncology; Perioperative Medicine |
| Phase | FDA-approved |
Mechanism of action
Ondansetron is a selective 5-HT3 receptor antagonist that prevents chemotherapy-induced and postoperative nausea and vomiting by blocking serotonin signaling in the chemoreceptor trigger zone and gastrointestinal tract. Dyclonine hydrochloride is a local anesthetic that numbs mucous membranes. This combination formulation likely targets both the central and peripheral mechanisms of nausea while providing topical anesthetic relief.
Approved indications
- Chemotherapy-induced nausea and vomiting (CINV)
- Postoperative nausea and vomiting (PONV)
- Radiation-induced nausea and vomiting
Common side effects
- Headache
- Constipation
- Diarrhea
- Fatigue
- Dizziness
- Local irritation (from dyclonine)
Key clinical trials
- Effect of Ondansetron on Patient Tolerance, Efficacy and Endoscopist Workload in Unsedated Endoscopy for Upper Gastrointestinal Bleeding (PHASE4)
- Oral Ondansetron to Improve Patient Experience of Unsedated Esophagogastroduodenoscopy Pilot Study (PHASE4)
- Ondansetron Combined with Dyclonine Hydrochloride to Improve Patient Experience in Unsedated Esophagogastro-duodenoscopy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: